Tempo reale stimato
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
66,51 USD | -1,12% | +3,56% | +7,58% |
Attività
Numero di dipendenti: 834
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
PYLARIFY
65,7
%
| 527 | 56,4 % | 851 | 65,7 % | +61,41% |
DEFINITY
21,6
%
| 245 | 26,2 % | 280 | 21,6 % | +14,19% |
TechneLite
6,7
%
| 89 | 9,5 % | 87 | 6,7 % | -1,68% |
Strategic Partnerships and Other
4,0
%
| 47 | 5,0 % | 52 | 4,0 % | +10,68% |
Other Precision Diagnostics
1,8
%
| 23 | 2,4 % | 23 | 1,8 % | +0,68% |
Other Radiopharmaceutical Oncology
0,2
%
| 4 | 0,4 % | 3 | 0,2 % | -23,70% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
97,4
%
| 901 | 96,4 % | 1 263 | 97,4 % | +40,08% |
International
2,6
%
| 34 | 3,6 % | 34 | 2,6 % | +0,13% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Brian Markison
CEO | Chief Executive Officer | 64 | 01/09/12 |
Paul Blanchfield
PSD | President | 43 | 27/01/20 |
Robert Marshall
DFI | Director of Finance/CFO | 57 | 21/09/18 |
Mary Heino
CHM | Chairman | 64 | 01/04/13 |
Iryna Teslenko
CTO | Chief Tech/Sci/R&D Officer | - | 07/04/21 |
Bela Denes
CTO | Chief Tech/Sci/R&D Officer | - | 07/04/21 |
Chief Tech/Sci/R&D Officer | 60 | 04/04/22 | |
Chief Administrative Officer | 47 | 01/09/13 | |
Mark Kinarney
IRC | Investor Relations Contact | - | 01/01/18 |
Linda S. Lennox
IRO | Public Communications Contact | 59 | 01/08/20 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Brian Markison
CEO | Chief Executive Officer | 64 | 01/09/12 |
James H. Thrall
BRD | Director/Board Member | 80 | 01/02/18 |
Sam Leno
BRD | Director/Board Member | 78 | 01/05/12 |
Mary Heino
CHM | Chairman | 64 | 01/04/13 |
Gary Pruden
BRD | Director/Board Member | 61 | 01/02/18 |
Julie McHugh
BRD | Director/Board Member | 59 | 01/01/17 |
Director/Board Member | 76 | 01/02/22 | |
Gérard Ber
BRD | Director/Board Member | 66 | 19/06/20 |
Director/Board Member | 61 | 19/06/20 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 69 890 404 | 66 792 699 ( 95,57 %) | 1 339 000 ( 1,916 %) | 95,57 % |
Partecipazioni
Nome | Azioni | % | Valorizzazione |
---|---|---|---|
116 773 394 | 19.90% | 138 960 339 $ |
Coordinate società
Lantheus Holdings, Inc.
201 Burlington Road South Building
01730, Bedford
+978 671 8001
http://www.lantheus.comSocietà del gruppo
Nome | Categoria e settore |
---|---|
Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc. Medical SpecialtiesHealth Technology Lantheus Medical Imaging, Inc. engages in the manufacture, marketing, sale, and distribution of medical imaging products. It provides diagnostic imaging and nuclear medicine products that assist clinicians with the detection of disease, primarily cardiovascular. Its product protfolio includes DEFINITY, TechneLite, Xenon, AZEDRA, Cardiolite, and NEUROLITE. The company was founded in 1956 and is headquartered in North Billerica, MA. |
Medical Specialties
|
Settore
Vendite per attività
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+7,78% | 4,61 Mrd | |
+0,40% | 12,95 Mrd | |
-7,57% | 7,84 Mrd | |
+2,10% | 5,5 Mrd | |
+0,02% | 4,61 Mrd | |
-48,20% | 3,4 Mrd | |
+9,21% | 2,66 Mrd | |
-14,59% | 2,08 Mrd | |
+2,25% | 1,79 Mrd | |
-11,63% | 1,72 Mrd |
- Borsa valori
- Azioni
- Azione LNTH
- Società Lantheus Holdings, Inc.